Abstract
Background Recombinant therapeutic proteins are increasingly requested with advances in tissue engineering using stem cells. Human cell line is an attractive host for the production of such glycoprotein, but there are few reports on human cells for a commercial production [1]. In this study, we established new human lymphoid cell lines from peripheral blood mononuclear cells (PBMCs) by treatment with phorbol 12-myristate 13-acetate (PMA) under a non-GMP condition, and characterized them by gene and protein expression analyses.
Highlights
Recombinant therapeutic proteins are increasingly requested with advances in tissue engineering using stem cells
Human cell line is an attractive host for the production of such glycoprotein, but there are few reports on human cells for a commercial production [1]
We established new human lymphoid cell lines from peripheral blood mononuclear cells (PBMCs) by treatment with phorbol 12-myristate 13-acetate (PMA) under a non-GMP condition, and characterized them by gene and protein expression analyses
Summary
Background Recombinant therapeutic proteins are increasingly requested with advances in tissue engineering using stem cells.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
